JAMDA
Volume 8, Issue 2 , Pages 83-90 , February 2007

Once-Monthly Darbepoetin alfa for Maintaining Hemoglobin Levels in Older Patients With Chronic Kidney Disease

  • Anil Agarwal, MD

      Affiliations

    • The Ohio State University Medical Center, Columbus, OH
    • A.A. and M.R.S. have received consultation fees and speaker honoraria from Amgen.
    • Corresponding Author InformationAddress correspondence to Anil Agarwal, MD, The Ohio State University Medical Center, N. 210 Means Hall, 1654 Upham Drive, Columbus, OH 43210.
    • ,
  • Marcia R. Silver, MD, FACP

      Affiliations

    • Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH
    • A.A. and M.R.S. have received consultation fees and speaker honoraria from Amgen.
    • ,
  • Michael Walczyk, MD

      Affiliations

    • Northwest Renal Clinic, Portland, OR
    • ,
  • Wei Liu

      Affiliations

    • Amgen Inc, Thousand Oaks, CA.
    • ,
  • Paul Audhya, MD

      Affiliations

    • Amgen Inc, Thousand Oaks, CA.

References 

  1. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: The Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003;42:22–35
  2. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  3. Garg AX, Papaioannou A, Ferko N, et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int. 2004;65:649–653
  4. Papaioannou A, Ray JG, Ferko NC, et al. Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med. 2001;111:569–573
  5. He W, Sengupta M, Velkoff VA, et al. 65+ in the United States: 2005. Current Population Reports, Special Studies. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Aging; 2005;Issued December Available at: http://www.census.gov/prod/2006pubs/p23-209.pdf. Accessed April 5, 2006.
  6. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(Suppl 3):13–19
  7. Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37:395–402
  8. Narayanan S, Critchlow C, Sciarra A, et al. Chronic kidney disease (CKD)-associated anemia is common in elderly nursing-home residents. [abstract] J Am Soc Nephrol. 2005;16:549A
  9. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41:1364–1372
  10. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16:3728–3735
  11. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The Cardiovascular Health Study. Arch Intern Med. 2005;165:2214–2220
  12. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA. 1999;281:1714–1717
  13. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;87:S24–S31
  14. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  15. Herzog CA, Muster HA, Li S, et al. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail. 2004;10:467–472
  16. Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–2925
  17. Astor BC, Coresh J, Heiss G, et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151:492–500
  18. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955–962
  19. Levin A, Djurdjev O, Duncan J, et al. Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant. 2006;21:370–377
  20. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290–299
  21. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414–421
  22. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–2395
  23. Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet. 2006;45:503–510
  24. Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 2003;23:106–111
  25. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol. 2004;24:453–460
  26. Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327–334
  27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  28. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  29. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  30. Gouva C, Nikolopoulos P, Ioannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753–760
  31. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001;16:307–312
  32. Dean BB, Dylan M, Gano A, et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: A retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin. 2005;21:981–987
  33. Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29:541–548
  34. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35:250–256
  35. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548–554
  36. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004;61:392–405
  37. Hertel J, Locay H, Scarlata D, et al. Every-other-week Aranesp(R) (darbepoetin alfa) achieves and maintains target hemoglobin (Hb) levels and improves health-related quality of life (HRQOL) in recombinant human erythropoietin (rHuEPO)-naive patients with chronic kidney disease (CKD). [abstract] J Am Soc Nephrol. 2005;16:547A
  38. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001;60:741–747
  39. Bernardo M, Hertel J, Xu X, et al. Comparison of practice resources required to provide weekly (QW) versus monthly (QM) erythropoiesis stimulating protein (ESP) therapy. [abstract] Am J Kidney Dis. 2006;47:A18
  40. Hertel J, Crawford P, Mafilios M, et al. Cost minimization model evaluating resource utilization to nephrology practices treating patients with erythropoietic stimulating protein (ESP) on a monthly (QM) versus weekly (QW) basis. [abstract] Am J Kidney Dis. 2006;47:A34

PII: S1525-8610(06)00374-4

doi: 10.1016/j.jamda.2006.07.007

JAMDA
Volume 8, Issue 2 , Pages 83-90 , February 2007

Article Tools

* Image Usage & Resolution